
Topspin Partners
Description
Topspin Partners is a Mamaroneck, New York-based private equity firm with a history rooted in venture capital. Formed in 2000, it succeeded the Long Island Venture Fund, which began its investment activities in 1995. While its origins are in early-stage investing, Topspin Partners has evolved into a middle-market private equity firm, primarily focused on making control investments. This distinction is crucial, as their current strategy involves acquiring significant stakes in established companies rather than providing seed or early-stage venture capital.
The firm's investment strategy targets companies within the consumer, health & wellness, and related business services sectors. Topspin seeks businesses with strong fundamentals, proven management teams, and significant growth potential. They typically look for companies generating between $3 million and $15 million in EBITDA, indicating a focus on profitable, mature businesses rather than nascent startups. Their approach involves partnering with management to implement operational improvements and strategic initiatives aimed at accelerating growth and enhancing value.
Topspin Partners typically deploys substantial equity capital in its transactions. For each investment, the firm aims to commit between $15 million and $50 million of equity. This capital is used to facilitate buyouts, recapitalizations, and growth equity investments, always with the goal of achieving a controlling interest. The firm emphasizes a hands-on approach, leveraging its team's operational expertise to support portfolio companies through various stages of development, from strategic planning to market expansion and operational efficiency improvements. Their long-standing presence in the market, originating from a fund established over two decades ago, underscores their experience in private market investments.
Investor Profile
Topspin Partners has backed more than 48 startups, with 0 new investments in the last 12 months alone. The firm has led 16 rounds, about 33% of its total and boasts 15 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series C, Series B, Series Unknown rounds (top funding stages).
- Majority of deals are located in United States.
- Strong thematic focus on Biotechnology, Health Care, Medical.
- Typical check size: $15M – $50M.
Stage Focus
- Series C (23%)
- Series B (19%)
- Series Unknown (15%)
- Series D (10%)
- Series A (10%)
- Series E (8%)
- Private Equity (6%)
- Series F (4%)
- Seed (2%)
- Pre Seed (2%)
Country Focus
- United States (100%)
Industry Focus
- Biotechnology
- Health Care
- Medical
- Pharmaceutical
- Therapeutics
- Genetics
- Biopharma
- Manufacturing
- Analytics
- Software
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.